Extracellular 3′,5′-cAMP-adenosine pathway inhibits glomerular mesangial cell growth

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 808-815

  Dubey, Raghvendra K ^b,c   Rosselli, Marinella ^b   Gillespie, Delbert G ^a   Mi, Zaichuan ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIPROPYL 8 P SULFOPHENYLXANTHINE; 2', 5' DIDEOXYADENOSINE; 3', 5' CYCLIC AMP; 5 IODOTUBERCIDIN; 5' NUCLEOTIDASE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 BROMO 3',5' CYCLIC AMP; 8 CYCLOPENTYL 1, 3 DIPROPYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE KINASE; ADENOSINE RECEPTOR; ADENYLATE CYCLASE INHIBITOR; ALPHA BETA METHYLENE ADENOSINE 5' DIPHOSPHATE; CYCLIC AMP DERIVATIVE; FORSKOLIN; INOSINE; ISOBUTYLMETHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 METHOXYPHENYL) N' (2 [3 PYRIDINYL] 4 QUINAZOLINYL) UREA; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE A2B RECEPTOR; ADENYLATE CYCLASE; ANTISENSE OLIGONUCLEOTIDE; COLLAGEN; CYCLIC AMP; DNA; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MESANGIUM; METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR SPACE; GENETICS; MESANGIUM CELL; MITOSIS; PHYSIOLOGY;

ADENOSINE; ADENYLATE CYCLASE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYCLIC AMP; DNA; ENZYME INHIBITORS; EXTRACELLULAR SPACE; FORSKOLIN; HUMANS; MESANGIAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; OLIGONUCLEOTIDES, ANTISENSE; RATS; RECEPTOR, ADENOSINE A2B; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 77952378208     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166371     Document Type: Article

References (34)

1. Beavo JA and Reifsnyder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155. (Pubitemid 20118008)
2. Cheng D, Ren J, and Jackson EK (2010) Multidrug resistance protein 4 mediates cAMP efflux from rat preglomerular vascular smooth muscle cells. Clin Exp Pharmacol Physiol 37:205-207.
3. Chiavegatti T, Costa VL Jr, Araújo MS, and Godinho RO (2008) Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway. Br J Pharmacol 153:1331-1340. (Pubitemid 351415496)
4. Dubey RK, Gillespie DG, Osaka K, Suzuki F, and Jackson EK (1996a) Adenosine inhibits growth of rat aortic smooth muscle cells: possible role of A2b receptor. Hypertension 27:786-793. (Pubitemid 26084643)
5. 2B receptors. Hypertension 31:943-948.
6. Dubey RK, Gillespie DG, Mi Z, and Jackson EK (1997) Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96:2656-2666. (Pubitemid 27451359)
7. Dubey RK, Gillespie DG, Mi Z, and Jackson EK (1998b) Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 31:516-521. (Pubitemid 28124768)
8. Dubey RK, Gillespie DG, Mi Z, and Jackson EK (2001a) Endogenous cyclic AMPadenosine pathway regulates cardiac fibroblast growth. Hypertension 37:1095-1100. (Pubitemid 32304010)
9. 2B receptors. Hypertension 46:628-634.
10. Dubey RK, Gillespie DG, Shue H, and Jackson EK (2000a) A2B receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 35:267-272. (Pubitemid 30054184)
11. Dubey RK, Gillespie DG, Zacharia LC, Mi Z, and Jackson EK (2001b) A2B receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension 37:716-721. (Pubitemid 32199055)
12. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B, and Keller PJ (2000b) Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol 20:964-972. (Pubitemid 30207569)
13. Dubey RK, Mi Z, Gillespie DG, and Jackson EK (1996b) Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth. Hypertension 28:765-771. (Pubitemid 26365516)
14. Giron MC, Bin A, Brun P, Etteri S, Bolego C, Florio C, and Gaion RM (2008) Cyclic AMP in rat ileum: evidence for the presence of an extracellular cyclic AMP-adenosine pathway. Gastroenterology 134:1116-1126. (Pubitemid 351451977)
15. Ijzerman AP and Van Der Wenden NM (1997) Modulators of adenosine uptake, release, and inactivation, in Purinergic Approaches in Experimental Therapeutics (Jacobson KA and Jarvis MF eds) pp 129-148, Willey-Liss, Inc., New York.
16. Inoue T, Mi Z, Gillespie DG, and Jackson EK (1998) Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. Eur J Pharmacol 361:285-291. (Pubitemid 29000984)
17. Insel PA and Ostrom RS (2003) Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol 23:305-314.
18. Jackson EK and Dubey RK (2001) Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol 281:F597-F612. (Pubitemid 32946725)
19. Jackson EK and Mi Z (2000) Preglomerular microcirculation expresses the cAMPadenosine pathway. J Pharmacol Exp Ther 295:23-28.
20. Jackson EK, Mi Z, Koehler MT, Carcillo JA Jr, and Herzer WA (1996) Injured erythrocytes release adenosine deaminase into the circulation. J Pharmacol Exp Ther 279:1250-1260. (Pubitemid 27166772)
21. Jacobson KA and Knutsen LJS (2001) P1 and P2 purine and pyrimidine receptor ligands, in Purinergic and Pyrmidinergic Signaling I (Abbracchio MP and Williams M eds) pp 129-175, Springer-Verlag, Berlin, Germany.
22. Johnson RA, Yeung SM, Stübner D, Bushfield M, and Shoshani I (1989) Cation and structural requirements for P site-mediated inhibition of adenylate cyclase. Mol Pharmacol 35:681-688. (Pubitemid 19138918)
23. Kwoh C, Shannon MB, Miner JH, and Shaw A (2006) Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 1:349-374.
24. LeHir M and Kriz W (2007) New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens 16:184-191. (Pubitemid 46608525)
25. 2, and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets. Biochemistry 47:1259-1273.
26. Schlöndorff D and Banas B (2009) The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 20:1179-1187.
27. Tofovic SP, Branch KR, Oliver RD, Magee WD, and Jackson EK (1991) Caffeine potentiates vasodilator-induced renin release. J Pharmacol Exp Ther 256:850-860.
28. Vallon V, Mühlbauer B, and Osswald H (2006) Adenosine and kidney function. Physiol Rev 86:901-940.
29. van Muijlwijk-Koezen JE, Timmerman H, van der Goot H, Menge WM, Frijtag Von Drabbe Künzel J, de Groote M, and IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem 43:2227-2238. (Pubitemid 30354547)
30. Yao J, Kitamura M, Zhu Y, Meng Y, Kasai A, Hiramatsu N, Morioka T, Takeda M, and Oite T (2006) Synergistic effects of PDGF-BB and cAMP-elevating agents on expression of connexin43 in mesangial cells. Am J Physiol Renal Physiol 290:F1083-F1093. (Pubitemid 43724907)
31. Yao J, Zhu Y, Sun W, Sawada N, Hiramatsu N, Takeda M, and Kitamura M (2007) Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signaling pathways and suppression of mesangial cell mitogenesis. Br J Pharmacol 151:457-466. (Pubitemid 46908558)
32. Zhu Y, Yao J, Meng Y, Kasai A, Hiramatsu N, Hayakawa K, Miida T, Takeda M, Okada M, and Kitamura M (2006) Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system. Br J Pharmacol 148:833-844. (Pubitemid 44079413)
33. Zimmermann H (1992) 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285:345-365.
34. Zimmermann H (2006) Ectonucleotidases in the nervous system. Novartis Found Symp 276:113-128.